-
1
-
-
0029082781
-
Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy
-
Uchida, N., N. Kurata, K. Shimada, Y. Nishimura, K. Yasuda, M. Hashimoto, E. Uchida, and H. Yasuhara. 1995. Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy. Jpn. J. Pharmacol. 68: 431-439.
-
(1995)
Jpn. J. Pharmacol
, vol.68
, pp. 431-439
-
-
Uchida, N.1
Kurata, N.2
Shimada, K.3
Nishimura, Y.4
Yasuda, K.5
Hashimoto, M.6
Uchida, E.7
Yasuhara, H.8
-
2
-
-
0033782903
-
Decreased in vivo metabolism of drugs in chronic renal failure
-
Leblond, F. A., L. Giroux, J. P. Villeneuve, and V. Pichette. 2000. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab. Dispos. 28: 1317-1320.
-
(2000)
Drug Metab. Dispos
, vol.28
, pp. 1317-1320
-
-
Leblond, F.A.1
Giroux, L.2
Villeneuve, J.P.3
Pichette, V.4
-
3
-
-
0035146107
-
Downregulation of hepatic cytochrome P450 in chronic renal failure
-
Leblond, F., C. Guévin, C. Demers, I. Pellerin, M. Gascon-Barré, and V. Pichette. 2001. Downregulation of hepatic cytochrome P450 in chronic renal failure. J. Am. Soc. Nephrol. 12: 326-332.
-
(2001)
J. Am. Soc. Nephrol
, vol.12
, pp. 326-332
-
-
Leblond, F.1
Guévin, C.2
Demers, C.3
Pellerin, I.4
Gascon-Barré, M.5
Pichette, V.6
-
4
-
-
0142074311
-
Down-regulation of hepatic CYP3A in chronic renal insufficiency
-
Rege, B., R. Krieg, N. Gao, and M. A. Sarkar. 2003. Down-regulation of hepatic CYP3A in chronic renal insufficiency. Pharm. Res. 20: 1600-1606.
-
(2003)
Pharm. Res
, vol.20
, pp. 1600-1606
-
-
Rege, B.1
Krieg, R.2
Gao, N.3
Sarkar, M.A.4
-
5
-
-
79960615869
-
Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats
-
Naud, J., J. Michaud, S. Beauchemin, M. J. Hébert, M. Roger, S. Lefrancois, F. A. Leblond, and V. Pichette. 2011. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug Metab. Dispos. 39: 1363-1369.
-
(2011)
Drug Metab. Dispos
, vol.39
, pp. 1363-1369
-
-
Naud, J.1
Michaud, J.2
Beauchemin, S.3
Hébert, M.J.4
Roger, M.5
Lefrancois, S.6
Leblond, F.A.7
Pichette, V.8
-
6
-
-
84857994282
-
Comparative study on altered hepatic metabolism of CYP3A substrates in rats with glycerol-induced acute renal failure
-
Kusaba, J., N. Kajikawa, H. Kawasaki, Y. Kurosaki, and T. Aiba. 2012. Comparative study on altered hepatic metabolism of CYP3A substrates in rats with glycerol-induced acute renal failure. Biopharm. Drug Dispos. 33: 22-29.
-
(2012)
Biopharm. Drug Dispos
, vol.33
, pp. 22-29
-
-
Kusaba, J.1
Kajikawa, N.2
Kawasaki, H.3
Kurosaki, Y.4
Aiba, T.5
-
7
-
-
0037539996
-
Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease
-
Dowling, T. C., A. E. Briglia, J. C. Fink, D. S. Hanes, P. D. Light, L. Stackiewicz, C. S. Karyekar, N. D. Eddington, M. R. Weir, and W. L. Henrich. 2003. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin. Pharmacol. Ther. 73: 427-434.
-
(2003)
Clin. Pharmacol. Ther
, vol.73
, pp. 427-434
-
-
Dowling, T.C.1
Briglia, A.E.2
Fink, J.C.3
Hanes, D.S.4
Light, P.D.5
Stackiewicz, L.6
Karyekar, C.S.7
Eddington, N.D.8
Weir, M.R.9
Henrich, W.L.10
-
8
-
-
67649360564
-
Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients
-
Kirwan, C. J., T. Lee, D. W. Holt, R. M. Grounds, I. A. MacPhee, and B. J. Philips. 2009. Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients. Intensive Care Med. 35: 1271-1275.
-
(2009)
Intensive Care Med
, vol.35
, pp. 1271-1275
-
-
Kirwan, C.J.1
Lee, T.2
Holt, D.W.3
Grounds, R.M.4
Macphee, I.A.5
Philips, B.J.6
-
9
-
-
84859927163
-
Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients
-
Kirwan, C. J., I. A. MacPhee, T. Lee, D. W. Holt, and B. J. Philips. 2012. Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients. Intensive Care Med. 38: 76-84.
-
(2012)
Intensive Care Med
, vol.38
, pp. 76-84
-
-
Kirwan, C.J.1
Macphee, I.A.2
Lee, T.3
Holt, D.W.4
Philips, B.J.5
-
10
-
-
0036897793
-
Down-regulation of hepatic cytochrome p450 in chronic renal failure: Role of uremic mediators
-
Guévin, C., J. Michaud, J. Naud, F. A. Leblond, and V. Pichette. 2002. Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br. J. Pharmacol. 137: 1039-1046.
-
(2002)
Br. J. Pharmacol
, vol.137
, pp. 1039-1046
-
-
Guévin, C.1
Michaud, J.2
Naud, J.3
Leblond, F.A.4
Pichette, V.5
-
11
-
-
33746364150
-
Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes
-
Hanada, K., R. Ogawa, K. Son, Y. Sasaki, A. Kikkawa, S. Ichihara, and H. Ogata. 2006. Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes. Nephron. Physiol. 103: 179-186.
-
(2006)
Nephron. Physiol
, vol.103
, pp. 179-186
-
-
Hanada, K.1
Ogawa, R.2
Son, K.3
Sasaki, Y.4
Kikkawa, A.5
Ichihara, S.6
Ogata, H.7
-
12
-
-
33748055777
-
Hemodialysis acutely improves hepatic CYP3A4 metabolic activity
-
Nolin, T. D., K. Appiah, S. A. Kendrick, P. Le, E. McMonagle, and J. Himmelfarb. 2006. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J. Am. Soc. Nephrol. 17: 2363-2367.
-
(2006)
J. Am. Soc. Nephrol
, vol.17
, pp. 2363-2367
-
-
Nolin, T.D.1
Appiah, K.2
Kendrick, S.A.3
Le, P.4
McMonagle, E.5
Himmelfarb, J.6
-
13
-
-
55549146147
-
Effect of hemodialysis on hepatic cytochrome P450 functional expression
-
Michaud, J., T. D. Nolin, J. Naud, M. Dani, J. P. Lafrance, F. A. Leblond, J. Himmelfarb, and V. Pichette. 2008. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J. Pharmacol. Sci. 108: 157-163.
-
(2008)
J. Pharmacol. Sci
, vol.108
, pp. 157-163
-
-
Michaud, J.1
Nolin, T.D.2
Naud, J.3
Dani, M.4
Lafrance, J.P.5
Leblond, F.A.6
Himmelfarb, J.7
Pichette, V.8
-
14
-
-
84864289543
-
Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation
-
Molanaei, H., P. Stenvinkel, A. R. Qureshi, J. J. Carrero, O. Heimbürger, B. Lindholm, U. Diczfalusy, I. Odar-Cederlöf, and L. Bertilsson. 2012. Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation. Eur. J. Clin. Pharmacol. 68: 571-577.
-
(2012)
Eur. J. Clin. Pharmacol
, vol.68
, pp. 571-577
-
-
Molanaei, H.1
Stenvinkel, P.2
Qureshi, A.R.3
Carrero, J.J.4
Heimbürger, O.5
Lindholm, B.6
Diczfalusy, U.7
Odar-Cederlöf, I.8
Bertilsson, L.9
-
15
-
-
0034007388
-
Phenotyping of drug-metabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes
-
Streetman, D. S., J. S. Jr. Bertino, and A. N. Nafziger. 2000. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 10: 187-216.
-
(2000)
Pharmacogenetics
, vol.10
, pp. 187-216
-
-
Streetman, D.S.1
Bertino Jr., J.S.2
Nafziger, A.N.3
-
16
-
-
0026341491
-
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin on urinary 6 beta-hydroxycortisol excretion: A preliminary study
-
Karayalçin, U., Y. Takeda, I. Miyamori, T. Morise, and R. Takeda. 1991. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin on urinary 6 beta-hydroxycortisol excretion: a preliminary study. Steroids. 56: 598-600.
-
(1991)
Steroids
, vol.56
, pp. 598-600
-
-
Karayalçin, U.1
Takeda, Y.2
Miyamori, I.3
Morise, T.4
Takeda, R.5
-
17
-
-
0347361482
-
Urinary 6beta-hydroxycortisol: A validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals
-
Galteau, M. M., and F. Shamsa. 2003. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur. J. Clin. Pharmacol. 59: 713-733.
-
(2003)
Eur. J. Clin. Pharmacol
, vol.59
, pp. 713-733
-
-
Galteau, M.M.1
Shamsa, F.2
-
18
-
-
0035914368
-
Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: Evidence for involvement of cytochrome p450 3A4
-
Bodin, K., L. Bretillon, Y. Aden, L. Bertilsson, U. Broomé, C. Einarsson, and U. Diczfalusy. 2001. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J. Biol. Chem. 276: 38685-38689.
-
(2001)
J. Biol. Chem
, vol.276
, pp. 38685-38689
-
-
Bodin, K.1
Bretillon, L.2
Aden, Y.3
Bertilsson, L.4
Broomé, U.5
Einarsson, C.6
Diczfalusy, U.7
-
19
-
-
42149130238
-
Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy
-
Wide, K., H. Larsson, L. Bertilsson, and U. Diczfalusy. 2008. Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. Br. J. Clin. Pharmacol. 65: 708-715.
-
(2008)
Br. J. Clin. Pharmacol
, vol.65
, pp. 708-715
-
-
Wide, K.1
Larsson, H.2
Bertilsson, L.3
Diczfalusy, U.4
-
20
-
-
33746255673
-
Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin
-
Niemi, M., K. T. Kivistö, U. Diczfalusy, K. Bodin, L. Bertilsson, M. F. Fromm, and M. Eichelbaum. 2006. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet. Genomics. 16: 565-568.
-
(2006)
Pharmacogenet. Genomics
, vol.16
, pp. 565-568
-
-
Niemi, M.1
Kivistö, K.T.2
Diczfalusy, U.3
Bodin, K.4
Bertilsson, L.5
Fromm, M.F.6
Eichelbaum, M.7
-
21
-
-
58149129621
-
4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin
-
Diczfalusy, U., K. P. Kanebratt, E. Bredberg, T. B. Andersson, Y. Böttiger, and L. Bertilsson. 2009. 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br. J. Clin. Pharmacol. 67: 38-43.
-
(2009)
Br. J. Clin. Pharmacol
, vol.67
, pp. 38-43
-
-
Diczfalusy, U.1
Kanebratt, K.P.2
Bredberg, E.3
Andersson, T.B.4
Böttiger, Y.5
Bertilsson, L.6
-
22
-
-
45849151673
-
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels
-
Josephson, F., L. Bertilsson, Y. Böttiger, L. Flamholc, M. Gisslén, V. Ormaasen, A. Sönnerborg, and U. Diczfalusy. 2008. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. Eur. J. Clin. Pharmacol. 64: 775-781.
-
(2008)
Eur. J. Clin. Pharmacol
, vol.64
, pp. 775-781
-
-
Josephson, F.1
Bertilsson, L.2
Böttiger, Y.3
Flamholc, L.4
Gisslén, M.5
Ormaasen, V.6
Sönnerborg, A.7
Diczfalusy, U.8
-
23
-
-
80053013798
-
Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LCESI- MS/MS analysis
-
Goodenough, A. K., J. M. Onorato, Z. Ouyang, S. Chang, A. D. Rodrigues, S. Kasichayanula, S. P. Huang, W. Turley, R. Burrell, M. Bifano, et al. 2011. Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LCESI- MS/MS analysis. Chem. Res. Toxicol. 24: 1575-1585.
-
(2011)
Chem. Res. Toxicol
, vol.24
, pp. 1575-1585
-
-
Goodenough, A.K.1
Onorato, J.M.2
Ouyang, Z.3
Chang, S.4
Rodrigues, A.D.5
Kasichayanula, S.6
Huang, S.P.7
Turley, W.8
Burrell, R.9
Bifano, M.10
-
24
-
-
71849114209
-
4betahydroxycholesterol as a marker of CYP3A4 inhibition in vivo - Effects of itraconazole in man
-
Lütjohann, D., M. Marinova, B. Schneider, J. Oldenburg, K. von Bergmann, T. Bieber, I. Björkhem, and U. Diczfalusy. 2009. 4betahydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man. Int. J. Clin. Pharmacol. Ther. 47: 709-715.
-
(2009)
Int. J. Clin. Pharmacol. Ther
, vol.47
, pp. 709-715
-
-
Lütjohann, D.1
Marinova, M.2
Schneider, B.3
Oldenburg, J.4
Von Bergmann, K.5
Bieber, T.6
Björkhem, I.7
Diczfalusy, U.8
-
25
-
-
40049103597
-
4Beta-hydroxycholesterol is a new endogenous CYP3A marker: Relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians
-
Diczfalusy, U., J. Miura, H. K. Roh, R. A. Mirghani, J. Sayi, H. Larsson, K. G. Bodin, A. Allqvist, M. Jande, J. W. Kim, et al. 2008. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet. Genomics. 18: 201-208.
-
(2008)
Pharmacogenet. Genomics
, vol.18
, pp. 201-208
-
-
Diczfalusy, U.1
Miura, J.2
Roh, H.K.3
Mirghani, R.A.4
Sayi, J.5
Larsson, H.6
Bodin, K.G.7
Allqvist, A.8
Jande, M.9
Kim, J.W.10
-
26
-
-
30144443733
-
Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation
-
Yilmaz, M. I., M. Saglam, K. Caglar, E. Cakir, T. Ozgurtas, A. Sonmez, T. Eyileten, M. Yenicesu, C. Acikel, Y. Oguz, et al. 2005. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation. 80: 1660-1666.
-
(2005)
Transplantation
, vol.80
, pp. 1660-1666
-
-
Yilmaz, M.I.1
Saglam, M.2
Caglar, K.3
Cakir, E.4
Ozgurtas, T.5
Sonmez, A.6
Eyileten, T.7
Yenicesu, M.8
Acikel, C.9
Oguz, Y.10
-
27
-
-
17844369761
-
Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients
-
Simmons, E. M., A. Langone, M. T. Sezer, J. P. Vella, P. Recupero, J. D. Morrow, T. A. Ikizler, and J. Himmelfarb. 2005. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation. 79: 914-919.
-
(2005)
Transplantation
, vol.79
, pp. 914-919
-
-
Simmons, E.M.1
Langone, A.2
Sezer, M.T.3
Vella, J.P.4
Recupero, P.5
Morrow, J.D.6
Ikizler, T.A.7
Himmelfarb, J.8
-
28
-
-
0016916438
-
Prediction of creatinine clearance from serum creatinine
-
Cockcroft, D.W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron. 16: 31-41.
-
(1976)
Nephron
, vol.16
, pp. 31-41
-
-
Cockcroft, D.W.1
Gault, M.H.2
-
29
-
-
79956084944
-
A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4 - -hydroxycholesterol in human plasma
-
van de Merbel, N. C., K. J. Bronsema, M. W. van Hout, R. Nilsson, and H. Sillén. 2011. A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4 - -hydroxycholesterol in human plasma. J. Pharm. Biomed. Anal. 55: 1089-1095.
-
(2011)
J. Pharm. Biomed. Anal
, vol.55
, pp. 1089-1095
-
-
Van De Merbel, N.C.1
Bronsema, K.J.2
Van Hout, M.W.3
Nilsson, R.4
Sillén, H.5
-
30
-
-
70349902844
-
ESRD impairs nonrenal clearance of fexofenadine but not midazolam
-
Nolin, T. D., R. F. Frye, P. Le, H. Sadr, J. Naud, F. A. Leblond, V. Pichette, and J. Himmelfarb. 2009. ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J. Am. Soc. Nephrol. 20: 2269-2276.
-
(2009)
J. Am. Soc. Nephrol
, vol.20
, pp. 2269-2276
-
-
Nolin, T.D.1
Frye, R.F.2
Le, P.3
Sadr, H.4
Naud, J.5
Leblond, F.A.6
Pichette, V.7
Himmelfarb, J.8
-
31
-
-
0142150027
-
Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans
-
Furuta, T., A. Suzuki, C. Mori, H. Shibasaki, A. Yokokawa, and Y. Kasuya. 2003. Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans. Drug Metab. Dispos. 31: 1283-1287.
-
(2003)
Drug Metab. Dispos
, vol.31
, pp. 1283-1287
-
-
Furuta, T.1
Suzuki, A.2
Mori, C.3
Shibasaki, H.4
Yokokawa, A.5
Kasuya, Y.6
-
32
-
-
0031868142
-
Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: Applications and recommendations
-
Kovacs, S. J., D. E. Martin, D. E. Everitt, S. D. Patterson, and D. K. Jorkasky. 1998. Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin. Pharmacol. Ther. 63: 617-622.
-
(1998)
Clin. Pharmacol. Ther
, vol.63
, pp. 617-622
-
-
Kovacs, S.J.1
Martin, D.E.2
Everitt, D.E.3
Patterson, S.D.4
Jorkasky, D.K.5
-
33
-
-
0037200017
-
Metabolism of 4 beta-hydroxycholesterol in humans
-
Bodin, K., U. Andersson, E. Rystedt, E. Ellis, M. Norlin, I. Pikuleva, G. Eggertsen, I. Björkhem, and U. Diczfalusy. 2002. Metabolism of 4 beta-hydroxycholesterol in humans. J. Biol. Chem. 277: 31534-31540.
-
(2002)
J. Biol. Chem
, vol.277
, pp. 31534-31540
-
-
Bodin, K.1
Andersson, U.2
Rystedt, E.3
Ellis, E.4
Norlin, M.5
Pikuleva, I.6
Eggertsen, G.7
Björkhem, I.8
Diczfalusy, U.9
-
34
-
-
67651183629
-
Plasma 4beta-hydroxycholesterol: An endogenous CYP3A metric?
-
Tomalik-Scharte, D., D. Lütjohann, O. Doroshyenko, D. Frank, A. Jetter, and U. Fuhr. 2009. Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? Clin. Pharmacol. Ther. 86: 147-153.
-
(2009)
Clin. Pharmacol. Ther
, vol.86
, pp. 147-153
-
-
Tomalik-Scharte, D.1
Lütjohann, D.2
Doroshyenko, O.3
Frank, D.4
Jetter, A.5
Fuhr, U.6
-
35
-
-
64749098311
-
Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS
-
Honda, A., K. Yamashita, T. Hara, T. Ikegami, T. Miyazaki, M. Shirai, G. Xu, M. Numazawa, and Y. Matsuzaki. 2009. Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. J. Lipid Res. 50: 350-357.
-
(2009)
J. Lipid Res
, vol.50
, pp. 350-357
-
-
Honda, A.1
Yamashita, K.2
Hara, T.3
Ikegami, T.4
Miyazaki, T.5
Shirai, M.6
Xu, G.7
Numazawa, M.8
Matsuzaki, Y.9
-
36
-
-
0034649068
-
Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients
-
Strehlau, J., L. Pape, G. Offner, B. Nashan, and J. H. Ehrich. 2000. Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet. 356: 1327-1328.
-
(2000)
Lancet
, vol.356
, pp. 1327-1328
-
-
Strehlau, J.1
Pape, L.2
Offner, G.3
Nashan, B.4
Ehrich, J.H.5
-
37
-
-
0035993387
-
Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients
-
Sifontis, N. M., E. Benedetti, and E. M. Vasquez. 2002. Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplant. Proc. 34: 1730-1732.
-
(2002)
Transplant. Proc
, vol.34
, pp. 1730-1732
-
-
Sifontis, N.M.1
Benedetti, E.2
Vasquez, E.M.3
-
39
-
-
40349108431
-
No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients
-
Kagaya, H., M. Miura, S. Satoh, K. Inoue, M. Saito, T. Inoue, T. Habuchi, and T. Suzuki. 2008. No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. J. Clin. Pharm. Ther. 33: 193-201.
-
(2008)
J. Clin. Pharm. Ther
, vol.33
, pp. 193-201
-
-
Kagaya, H.1
Miura, M.2
Satoh, S.3
Inoue, K.4
Saito, M.5
Inoue, T.6
Habuchi, T.7
Suzuki, T.8
-
40
-
-
5644239801
-
Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats
-
Konishi, H., M. Sumi, N. Shibata, K. Takada, T. Minouchi, and A. Yamaji. 2004. Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats. J. Pharm. Pharmacol. 56: 1259-1266.
-
(2004)
J. Pharm. Pharmacol
, vol.56
, pp. 1259-1266
-
-
Konishi, H.1
Sumi, M.2
Shibata, N.3
Takada, K.4
Minouchi, T.5
Yamaji, A.6
|